Similar companies
| Company | Business Outlook | |
|---|---|---|
 |
AmgenAMGN |
77 0% |
 |
Gilead SciencesGILD |
60 3.4% |
 |
Catalyst PharmaceuticalsCPRX |
100 0% |
 |
Inovio PharmaceuticalsINO |
23 0% |
 |
Anavex Life SciencesAVXL |
0 0% |
Month over Month
Employee view on business outlook (0 - 100)
| Nov 2024 | 54 | |
| Oct 2024 | 54 | |
| Sep 2024 | 59 | |
| Aug 2024 | 55 |
How do employees feel about the future at Incyte?
The Business Outlook at Incyte is neutral, according to employees. The average rating, aggregated from the top review sites in the US, of 56 out of 100 is decent. The rating is up, compared to previous month.
Analyzing Business Outlook, how is Incyte performing compared to its industry peers?
Compared to its peers, Incyte ranks in the 56th percentile when it comes to Business Outlook.
How has the business outlook at Incyte changed over the last couple of months
In recent months, Incyte's employees have reported a shift towards a more negative business outlook, suggesting declining company morale and potentially leading to decreased market competitiveness and diminished company performance.
Why is it important to track the business outlook at Incyte?
Tracking a company's business outlook is important as a positive outlook can indicate future growth and profitability and attract new talent, while a negative outlook can discourage talent and imply demotivated employees. Additionally, data shows that companies with a high business outlook tend to perform better on the stock market compared to those with a lower business outlook.
Sign up and get more insights on the business outlook at Incyte.
